{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "https://eldaddp.azurewebsites.net/answeredquestions.text?AnswerDate=2017-11-01&answeringDeptSortName=Health&version=2", "definition" : "https://eldaddp.azurewebsites.net/meta/answeredquestions.text?AnswerDate=2017-11-01&answeringDeptSortName=Health&version=2", "extendedMetadataVersion" : "https://eldaddp.azurewebsites.net/answeredquestions.text?AnswerDate=2017-11-01&answeringDeptSortName=Health&_metadata=all&version=2", "first" : "https://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&AnswerDate=2017-11-01&answeringDeptSortName=Health&version=2", "hasPart" : "https://eldaddp.azurewebsites.net/answeredquestions.text?AnswerDate=2017-11-01&answeringDeptSortName=Health&version=2", "isPartOf" : "https://eldaddp.azurewebsites.net/answeredquestions.text?AnswerDate=2017-11-01&answeringDeptSortName=Health&version=2", "items" : [{"_about" : "http://data.parliament.uk/resources/780519", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/780519/answer", "answerText" : {"_value" : "<p>The Medicines and Healthcare products Regulatory Agency (MHRA) encourages anyone to report a suspected adverse reaction (ADR) to a vaccine or medicine through the Yellow Card Scheme:<\/p><p> <\/p><p><a href=\"http://www.mhra.gov.uk/yellowcard\" target=\"_blank\">www.mhra.gov.uk/yellowcard<\/a><\/p><p>A Yellow Card report is not proof of a side effect occurring, but a suspicion by the reporter that the vaccine or medicine may have been the cause. Such reports are kept under continual review to identify potential new risks.<\/p><p> <\/p><p>Between 31 October 2014 \u2013 30 October 2017 a total of 649 serious suspected adverse reaction (ADR) reports with human papilloma virus (HPV) vaccines have been reported to the Medicines and Healthcare products Regulatory Agency (MHRA) via the Yellow Card Scheme (data run date: 1 November 2017). In this three year period, at least 1 million doses of HPV vaccine were administered in the United Kingdom.<\/p><p> <\/p><p>A breakdown of UK serious suspected spontaneous ADR reports received via the Yellow Card Scheme beween 31 October 2014 \u2013 30 October 2016 by brand and year received is shown in the following table.<\/p><p> <\/p><table><tbody><tr><td><p>HPV Vaccine<\/p><\/td><td><p>Number of serious reports<\/p><\/td><\/tr><tr><td><p>HPV brand unspecified<\/p><\/td><td><p>181<\/p><\/td><\/tr><tr><td><p>Cervarix<\/p><\/td><td><p>64<\/p><\/td><\/tr><tr><td><p>Gardasil<\/p><\/td><td><p>390<\/p><\/td><\/tr><tr><td><p>Gardasil 9<\/p><\/td><td><p>18<\/p><\/td><\/tr><tr><td><p>Total<\/p><\/td><td><p>649<\/p><\/td><\/tr><\/tbody><\/table><p> <\/p><p>Source: MHRA sentinel database for adverse reactions<\/p><p> <\/p><p>Notes:<\/p><p> <\/p><p>The total number of reports received by vaccine brand is not equal to the totals in the table above as some reports included more than one HPV vaccine brand.<\/p><p> <\/p><p>The MHRA has received a total of 3,159 serious suspected adverse reaction reports associated with HPV vaccine (data run date 1 November 2017).<\/p><p> <\/p><p>All serious reports received via the Yellow Card Scheme are reviewed based on the details received from the reporter. Follow up letters may be sent for missing information such as vaccine brand name, batch number, medical history, results of investigations, diagnoses and details of outcome.<\/p><p> <\/p><p>The Commission on Human Medicines has thoroughly reviewed the safety of HPV vaccines and concluded that the evidence does not support a link between HPV vaccination and the development of chronic illnesses.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2017-11-07", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "110248"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2017-11-07T11:31:40.833Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2017-10-30", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Human Papillomavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, how many Yellow Cards submitted to the Medicines and Healthcare Products Regulatory Agency for the HPV vaccination were classified as serious; and how many of those cases were reviewed to establish whether the patient had returned to full health in each of the last 12 months.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4663", "label" : {"_value" : "Biography information for Ben Bradley"}
      }
      , "tablingMemberConstituency" : {"_value" : "Mansfield"}
      , "tablingMemberPrinted" : [{"_value" : "Ben Bradley"}
      ], "uin" : "110360"}
    , {"_about" : "http://data.parliament.uk/resources/780529", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/780529/answer", "answerText" : {"_value" : "<p>The use of transanal submucosal resection techniques for bowel treatment on the National Health Service would be a decision for clinical commissioning groups (CCGs). NHS England expects CCGs to take account of the National Institute for Health and Care Excellence guidelines and local population needs when making commissioning decisions.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2017-11-07", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2017-11-07T11:47:57.58Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2017-10-30", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Digestive System: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, when he expects the transanal submucosal resection technique to be available for bowel treatment on the NHS.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
      }
      , "tablingMemberConstituency" : {"_value" : "Strangford"}
      , "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
      ], "uin" : "110405"}
    , {"_about" : "http://data.parliament.uk/resources/780547", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/780547/answer", "answerText" : {"_value" : "<p>The Department has made no such estimate. NHS England received £554.9 million in revenue from the National Health Service prescription charge for the financial year 2016/17. If all prescriptions had been free of charge that year, this is the revenue that would have been forgone.<\/p><p> <\/p><p>Source: Department of Health Annual Report and Accounts 2016-17<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2017-11-07", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2017-11-07T11:46:27.737Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2017-10-30", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Prescriptions: Fees and Charges"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what estimate he has made of the potential cost to the public purse of universal free prescriptions in NHS England.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3973", "label" : {"_value" : "Biography information for Grahame Morris"}
      }
      , "tablingMemberConstituency" : {"_value" : "Easington"}
      , "tablingMemberPrinted" : [{"_value" : "Grahame Morris"}
      ], "uin" : "110331"}
    ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 3, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}